Advances in Understanding “High on-Treatment Platelet Reactivity”

• References

• 1 Cesari F, Marcucci R, Caporale R. et al. Relationship between high platelet turnover and platelet function in high-risk patients with coronary artery disease on dual antiplatelet therapy. Thromb Haemost 2008; 99: 930-935.
• 2 Crescente M, Di Castelnuovo A, Iacoviello L. et al. PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a metaanalysis of 19 studies comprising 3,003 patients. Thromb Haemost 2008; 99: 1129-1131.
• 3 Crescente M, Di CA, Iacoviello L. et al. Response variability to aspirin as assessed by the platelet function analyzer (PFA)-100 A systematic review. Thromb Haemost 2008; 99: 14-26.
• 4 Gori AM, Marcucci R, Paniccia R. et al. Thrombotic events in high risk patients are predicted by evaluating different pathways of platelet function. Thromb Haemost 2008; 100: 1136-1145.
• 5 Gremmel T, Steiner S, Seidinger D. et al. Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation. Thromb Haemost 2009; 101: 333-339.
• 6 Guthikonda S, Mangalpally K, Vaduganathan M. et al. Increased platelet sensitivity among individuals with aspirin resistance - platelet aggregation to submaximal concentration of arachidonic acid predicts response to antiplatelet therapy. Thromb Haemost 2008; 100: 83-89.
• 7 Jakubowski JA, Payne CD, Li YG. et al. The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration. Thromb Haemost 2008; 99: 409-415.
• 8 Jakubowski JA, Payne CD, Li YG. et al. A comparison of the antiplatelet effects of prasugrel and highdose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry. Thromb Haemost 2008; 99: 215-222.
• 9 May AE, Geisler T, Gawaz M. Individualized antithrombotic therapy in high risk patients after coronary stenting A double-edged sword between thrombosis and bleeding. Thromb Haemost 2008; 99: 487-493.
• 10 Reny JL, Quere I, de Moerloose P. et al. Aspirin response variability assessed with the PFA-100 device. Thromb Haemost 2008; 99: 968-969.
• 11 Schafer A, Weinberger S, Flierl U. et al. ADP-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a P2Y12-specific assay. Thromb Haemost 2008; 100: 618-625.
• 12 Beres BJ, Toth-Zsamboki E, Vargova K. et al. Analysis of platelet alpha2-adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy. Thromb Haemost 2008; 100: 829-838.
• 13 Serebruany V, Pokov I, Kuliczkowski W. et al. Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease. Thromb Haemost 2008; 100: 76-82.
• 14 Zimmermann N, Hohlfeld T. Clinical implications of aspirin resistance. Thromb Haemost 2008; 100: 379-390.
• 15 Sibbing D, Morath T, Stegherr J. et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 2009; 101: 714-719.
• 16 Pettinella C, Romano M, Stuppia L. et al. Cyclooxygenase-1 haplotype C50T/A-842G does not affect platelet response to aspirin. Thromb Haemost 2009; 101: 687-690.
• 17 Kunicki TJ, Williams SA, Nugent DJ. et al. Lack of association between aspirin responsiveness and seven candidate gene haplotypes in patients with symptomatic vascular disease. Thromb Haemost 2009; 101: 123-133.
• 18 Baldit SC, Berge N, Boval B. et al. Functional variability of platelet response to clopidogrel correlates with P2Y(12) receptor occupancy. Thromb Haemost 2009; 101: 116-122.
• 19 Wong PC, Crain EJ, Watson CA. et al. Clopidogrel versus prasugrel in rabbits Effects on thrombosis, haemostasis, platelet function and response variability. Thromb Haemost 2009; 101: 108-115.
• 20 Breugelmans J, Vertessen F, Mertens G. et al. Multiplate whole blood impedance aggregometry: a recent experience. Thromb Haemost 2008; 100: 725-726.
• 21 Larson MK, Ashmore JH, Harris KA. et al. Effects of omega-3 acid ethyl esters and aspirin, alone and in combination, on platelet function in healthy subjects. Thromb Haemost 2008; 100: 634-641.
• 22 De Miguel A, Ibanez B, Badimon JJ. Clinical implications of clopidogrel resistance. Thromb Haemost 2008; 100: 196-203.
• 23 Braun OO, Johnell M, Vahrenhorst C. et al. Greater reduction of platelet activation markers and plateletmonocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease. Thromb Haemost 2008; 100: 626-633.
• 24 van Werkum JW, Topcu Y, Postma S. et al. Effects of diabetes mellitus on platelet reactivity after dual antiplatelet therapy with aspirin and clopidogrel. Thromb Haemost 2008; 99: 637-639.
• 25 Morel O, Bernhard N, Desprez D. et al. Residual prothrombotic status in low responder patients to clopidogrel identified by Vasodilator-Stimulated Phosphoprotein Phosphorylation (VASP) analysis?. Thromb Haemost 2008; 99: 448-451.
• 26 Neubauer H, Lask S, Engelhardt A. et al. How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification. Thromb Haemost 2008; 99: 357-362.
• 27 Trenk D, Hochholzer W, Frundi D. et al. Impact of cytochrome P450 3A4-metabolized statins on the antiplatelet effect of a 600-mg loading dose clopidogrel and on clinical outcome in patients undergoing elective coronary stent placement. Thromb Haemost 2008; 99: 174-181.
• 28 Angiolillo DJ, Bernardo E, Palazuelos J. et al. Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions Results of a randomized study. Thromb Haemost 2008; 99: 161-168.
• 29 Zeymer U, Gitt A, Junger C. et al. Clopidogrel in addition to aspirin reduces in-hospital major cardiac and cerebrovascular events in unselected patients with acute ST segment elevation myocardial. Thromb Haemost 2008; 99: 155-160.
• 30 Zeymer U, Gitt A, Junger C. et al. Efficacy and safety of enoxaparin in unselected patients with STsegment elevation myocardial infarction. Thromb Haemost 2008; 99: 150-154.
• 31 Sibbing D, Braun S, Jawansky S. et al. Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment. Thromb Haemost 2008; 99: 121-126.
• 32 Serebruany VL, Malinin AI, Hanley DF. Magnitude and time course of platelet inhibition with extended release dipyridamole with or without aspirin in healthy Japanese volunteers The AGgrenox versus Aspirin Therapy Evaluation (AGATE-Japan). Thromb Haemost 2008; 99: 116-120.
• 33 Blindt R, Stellbrink K, de Taeye A. et al. The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis. Thromb Haemost 2007; 98: 1329-1334.
• 34 Marcucci R, Paniccia R, Antonucci E. et al. Residual platelet reactivity is an independent predictor of myocardial injury in acute myocardial infarction patients on antiaggregant therapy. Thromb Haemost 2007; 98: 844-851.
• 35 Frere C, Cuisset T, Quilici J. et al. ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thromb Haemost 2007; 98: 838-843.
• 36 Rocca B, Patrono C. Determinants of the interindividual variability in response to antiplatelet drugs. J Thromb Haemost 2005; 03: 1597-1602.
• 37 Patrono C, Coller B, FitzGerald GA. et al. Plateletactive drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 234S-264S.
• 38 Becker RC, Meade TW, Berger PB. et al. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 776S-814S.
• 39 Cattaneo M, Hayward CP, Moffat KA. et al. Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry: a report from the platelet physiology subcommittee of the SSC of the ISTH. J Thromb Haemost 2009; 07: 1029.
• 40 Michelson AD, Cattaneo M, Eikelboom JW. et al. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost 2005; 03: 1309-1311.
• 41 Hayward CP, Eikelboom J. Platelet function testing: quality assurance. Semin Thromb Hemost 2007; 33: 273-282.
• 42 Elsenberg EHAM, van Werkum JW, van der Wal RMA. et al. The influence of clinical characterists, laboratory and inflammatory markers on „ high on-treatment platelet reactivity” as measured by different platelet function tests. Thromb Haemost 2009; 102: 719-727.